{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:43:20Z","timestamp":1794707000219,"version":"4.9.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.108087","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:34:18Z","timestamp":1755808458000},"page":"108087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia"],"prefix":"10.1016","volume":"157","author":[{"given":"Siri","family":"Ravipati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waffa","family":"Bakheet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indryas","family":"Woldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4480-0244","authenticated-orcid":false,"given":"Greg","family":"Yousif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeja","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-5935","authenticated-orcid":false,"given":"Abdulkadir","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cervi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopila","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindu","family":"Kanjeekal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-2088","authenticated-orcid":false,"given":"Caroline","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2025.108087_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2025.108087_bib2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108087_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.leukres.2025.108087_bib4","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year study results of DASISION: the dasatinib versus imatinib study in Treatment-Na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108087_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2025.108087_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.108087_bib7","unstructured":"Shah N., et al. NCCN Guidelines CML."},{"issue":"4","key":"10.1016\/j.leukres.2025.108087_bib8","doi-asserted-by":"crossref","first-page":"iv261","DOI":"10.1093\/annonc\/mdy159","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Hochhaus","year":"2018","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2025.108087_bib9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial [EURO-SKI] in chronic myeloid leukemia: final analysis and novel prognostic factors for Treatment-Free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108087_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The edmonton symptom assessment system 25 years later: past, present, and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J. Pain. Symptom Manag."},{"issue":"3","key":"10.1016\/j.leukres.2025.108087_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/10428194.2020.1838509","article-title":"Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia","volume":"62","author":"Efficace","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2025.108087_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2025.108087_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and, powerful approach to multiple testing","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B [Methodol.]"},{"issue":"1","key":"10.1016\/j.leukres.2025.108087_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108087_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-024-01025-7","article-title":"A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements","volume":"14","author":"Bonifacio","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2025.108087_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019000120","article-title":"Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission","volume":"134","author":"Shanmuganathan","year":"2019","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625005776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625005776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:29:16Z","timestamp":1772810956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625005776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":16,"alternative-id":["S0145212625005776"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108087","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108087"}}